Key Insights

Highlights

Success Rate

80% trial completion

Published Results

14 trials with published results (19%)

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 62/100

Termination Rate

13.5%

10 terminated out of 74 trials

Success Rate

80.4%

-6.1% vs benchmark

Late-Stage Pipeline

23%

17 trials in Phase 3/4

Results Transparency

34%

14 of 41 completed with results

Key Signals

14 with results80% success

Data Visualizations

Phase Distribution

63Total
Not Applicable (11)
P 1 (13)
P 2 (22)
P 3 (17)

Trial Status

Completed41
Terminated10
Not Yet Recruiting7
Unknown7
Recruiting5
Withdrawn2

Trial Success Rate

80.4%

Benchmark: 86.5%

Based on 41 completed trials

Clinical Trials (74)

Showing 20 of 20 trials
NCT05195710Phase 1RecruitingPrimary

Preoperative Y-90 Radioembolization for Tumor Control and Future Liver Remnant Hypertrophy in Patients With Colorectal Liver Metastases

NCT07594431Phase 2Not Yet RecruitingPrimary

Trial Comparing LATTICE Radiotherapy vs Moderately Dose-escalated Palliative Radiation for Patients With Metastases.

NCT07583914Phase 1Not Yet Recruiting

Safety, Tolerability, and Preliminary Antitumor Activity of Non-Cationic Peptide-CD47 siRNA in Advanced Solid Tumors

NCT07537946Phase 3Not Yet Recruiting

Local Consolidation After Sintilimab Plus Lenvatinib for Metastatic Liver Cancer

NCT07521826Not ApplicableNot Yet Recruiting

Exercise Training in Women With Metastatic Breast Cancer

NCT04987086Not ApplicableRecruiting

68Ga-PSMA PET in the Renal Cell Carcinoma

NCT07176312Phase 2Recruiting

Zanidatamab in Combination With Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroesophageal Adenocarcinoma (GEA) Patients

NCT07291895Not ApplicableNot Yet RecruitingPrimary

High Dose Radiotherapy for Palliation (Hi-D)

NCT02414269Phase 1Active Not Recruiting

Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin

NCT03977818Completed

Patterns of Care and Outcomes in METAstatic Soft Tissue SARComa

NCT07018505Not Yet Recruiting

EpCAM-Targeted Surface-Enhanced Raman Spectroscopy Nanotags for Rapid Evaluation of Surgical Margins and Sentinel Lymph Node Metastasis Status in Breast Cancers

NCT06937281Not ApplicableNot Yet Recruiting

SABR PRIMER - Evaluating Stereotactic Ablative Radiotherapy for Primary and Regional Breast Tumors

NCT06713161Recruiting

Tumor-Targeted-NIR-II Fluorescent Molecular Probes for the Identification of Breast Cancer Tissue and SLN Metastatic Status

NCT01678664Phase 2Completed

Everolimus After (Chemo)Embolization for Liver Metastases From Digestive Endocrine Tumors

NCT01442246Phase 3Active Not RecruitingPrimary

Evaluation of Adjuvant Hormonal Treatment for 24 Months After Radical Prostatectomy in High Risk of Recurrence Patients.

NCT01231347Phase 3Completed

QUILT-2.014: Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

NCT06356779Not ApplicableRecruiting

Longitudinal Study of Local Ablative Therapy in Oligometastatic Disease

NCT04967001Not ApplicableUnknown

68Ga-PSMA PET in the Prostate Cancer

NCT02301858Not ApplicableUnknown

Identification of Predictive and Prognostic Markers for Lung Cancer With Metastases

NCT00807859Phase 1Completed

Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer

Scroll to load more

Research Network

Activity Timeline